Patents by Inventor Vassiliki KARANTZA

Vassiliki KARANTZA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING METASTATIC TRIPLE NEGATIVE BREAST CANCER WITH ANTI-PD-1 ANTIBODIES
    Publication number: 20220380469
    Abstract: The present invention relates to methods for treating metastatic triple negative breast cancer in a human patient which has been identified as having a PD-L1 enriched tumor comprising administering, as monotherapy, an anti-PD-1 antibody or antigen binding fragment thereof (e.g., pembrolizumab) in specific amounts to the patient about every three or six weeks, wherein the PD-L1 enriched tumor is a tumor identified as having a CPS score of ?10.
    Type: Application
    Filed: September 23, 2020
    Publication date: December 1, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gursel Aktan, Roger Delemere Dansey, Vassiliki Karantza, Zifang Guo, Jaime A. Mejia, Shu-Chih Su, Jing Zhao, Xuan Zhou
  • Combination of a PD-1 antagonist and eribulin for treating cancer
    Patent number: 10945990
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD., MERCK SHARP & DOHME CORP.
    Inventors: Junji Matsui, Gursel Aktan, Vassiliki Karantza, RuiRong Yuan, Yasuhiro Funahashi, Erhan Berrak
  • COMBINATION OF A PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER
    Publication number: 20180071247
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: March 3, 2016
    Publication date: March 15, 2018
    Applicants: MERCK SHARP & DOHME CORP., Eisai R&D Management Co., Ltd.
    Inventors: Junji MATSUI, Gursel AKTAN, Vassiliki KARANTZA, RuiRong YUAN, Yasuhiro FUNAHASHI, Erhan BERRAK